Beaufond Plc , a global leader in Active Pharmaceutical Ingredients (API) and specialty chemicals distribution headquartered in the Dubai International Financial Centre (DIFC), today announced the sanction of a USD 100 Million Line of Credit by First Abu Dhabi Bank PJSC (FAB), one of the UAE’s largest and most internationally recognised financial institutions.
The facility, comprises two integrated trade finance instruments: a USD 100 Million Letter of Guarantee facility (encompassing customs, performance, and bid bond guarantees) and a sub-limit of USD 100 Million for Import Letters of Credit (sight and usance) with a maximum usance tenor of 270 days. The line of credit has been structured to support Beaufond’s working capital requirements and the global procurement of pharmaceutical goods and related products from Beaufond’s international network of over 100 certified Contract Manufacturing Organisation (CMO) partners & suppliers.
USD 100M | USD 3.035B | USD 198.60 M | 270 Days |
FAB Credit Line | FY25 Audited Revenue | FY25 EBITDA | Max LC Tenor |
Lender | First Abu Dhabi Bank PJSC (FAB) |
Facility Amount | USD 100,000,000 (One Hundred Million US Dollars) |
Facility Type | Line of Credit — Letter of Guarantee + Import LC (Sub-Limit) |
Letter of Guarantee | USD 100,000,000 (Customs, Performance, Bid Bond Guarantees) |
Import LC Sub-Limit | USD 100,000,000 — Maximum usance tenor of 270 days |
Borrower | Beaufond Plc |
Purpose | Working capital; pharmaceutical goods procurement; trade finance support |
Mr. A. Kumar, Chief Operating Officer, Beaufond Plc
“The sanction of this USD 100 million line of credit by First Abu Dhabi Bank is a significant milestone for Beaufond and a clear validation of our financial standing and institutional credibility. FAB is one of the most respected banking institutions in the MENA region and globally, and their confidence in our credit profile reinforces what our Investment rating reflects — a company with exceptional balance sheet strength, best-in-class receivables quality. This facility further strengthens our trade finance infrastructure as we scale our pharmaceutical distribution platform toward the next phase of growth.”
Mr. Aman Dutta, Chief Financial Officer, Beaufond Plc
“This FAB facility represents an important step in diversifying and deepening Beaufond’s banking relationships ahead of our planned USD 500 million revolving working capital facility and our longer-term KIZAD manufacturing transition. The ability to draw on Letters of Credit and Guarantees from a bank of FAB’s calibre gives our global pharmaceutical supplier network — spanning Asia, Europe, and the Americas — additional confidence in Beaufond as a financially robust and institutionally backed counterparty.”
Letters of Guarantee — The USD 100 million guarantee line covers customs duty guarantees, performance guarantees for supply and works contracts, and bid bond guarantees supporting Beaufond’s participation in public and private pharmaceutical procurement tenders across the UAE and internationally.
Import Letters of Credit — Structured with a maximum usance tenor of 270 days to facilitate procurement of finished pharmaceutical formulations, medical and healthcare-related products, and pharmaceutical raw materials and intermediates from Beaufond’s global supplier network, principally across Europe and Asia.
The FAB facility sanction follows Beaufond’s strongest financial year to date. Key audited financial metrics for FY2024-25 are as follows:
FY25 Audited Revenue | USD 3,035 Million (+33.8% YoY) |
FY25 EBITDA | USD 198.6 Million (6.5% margin; +86.9% YoY) |
Net Profit to Shareholders | USD 177.5 Million (+67.3% YoY) |
Total Equity | USD 896.8 Million (+49.2% YoY) |
Funded Debt | USD 0.94 Million (effectively zero — debt-free enterprise) |
Cash & Equivalents | USD 160.3 Million (+138% YoY) |
Current Ratio | 2.14x (above 1.5x institutional benchmark) |
Interest Coverage Ratio | 1,991x (current) — exceptional debt service capacity |
Receivables Recovery Rate | ~99.97% — best-in-class vs. 95–99% industry peers |
Trade Receivables Portfolio | USD 1,009.3 Million (audited) — zero >180 days overdue in FY25 |
5-Year Revenue CAGR | 22.7% — significantly exceeds 8–15% industry average |
The FAB sanction forms part of Beaufond’s structured institutional banking strategy, The company is also progressing the KIZAD (Khalifa Industrial Zone Abu Dhabi) greenfield pharmaceutical manufacturing facility — a USD 1.0–1.15 billion project backed by a USD 612 million commitment from Nomas Global Investments LLC-SPC (70% shareholder, wholly owned by H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan of the Abu Dhabi ruling family) — targeting commissioning in FY2027-28.
Beaufond is transitioning is advancing IPO preparatory activities, with a target listing on a major international exchange in FY2027-28 following KIZAD commissioning.
Beaufond Plc is a DIFC-registered global pharmaceutical chemicals and specialty chemicals distributor, incorporated in 2009 and operating across 50+ countries through 32 offices in 17 countries. The company distributes APIs and specialty chemicals to global pharmaceutical majors under five-to-seven-year rolling supply contracts.
First Abu Dhabi Bank PJSC (FAB) is the UAE’s largest bank by assets and one of the largest and safest financial institutions in the world. Headquartered in Abu Dhabi, FAB offers a full suite of commercial, investment, and trade finance services across its extensive domestic and international network.
Name | Role | |
Mr. Christopher Lynn | Media & Communication Desk | media.relations@beaufond.com |
DISCLAIMER
This press release contains forward-looking statements based on current expectations and projections. Actual results may differ materially from those anticipated. All financial figures cited are sourced from the FY2024-25 Audited Annual Report of Beaufond Plc (audited by Youssry & Co, DIFC Empanel-registered, December 2025). This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. © 2026 Beaufond Plc. All Rights Reserved. DIFC Registration No. 3122.
Global Headquarters
Beaufond Plc #3502, Saeed Tower – 2, S.Z Road Near Financial Centre Metro Station, Dubai, United Arab Emirates
Contact Information
Tel: +971-4-575-1343 | Email: info@beaufond.com
Business Hours: Monday – Friday, 09:00 AM – 18:00 PM